Results at 28 weeks: Placebo-subtracted weight loss: up to 14.1% (1.2 mg dose) Individual responses: as high as 26.5% Discontinuation rate: 2.9% total, with only 2 of 239 participants stopping due to adverse events The drug showed favorable tolerability compared to current GLP-1s, with lower rates of nausea and vomiting
In mouse models, dual agonism had superior efficacy for weight loss and glucose control compared to a GLP-1RA alone 9 , with additive effects of the GIPR proposed to act through signaling in beta cells 10 , alpha cells 11 , the CNS (central nervous system) 12,13 and adipocytes 14
Gastroenterology 154 , 238252 (2018)
So even if eat or not, into plants, and you want to eat meat, well, you're still going to get magnesium deficient because you're not getting it
Placebo patients were also assured with acute kidney failure, but only a mere four patients
Theres about 10% of patients that dont respond to GLP-1s, Spratt said